Hong Yanyan, Chen Tingting, He Qian, Ma Qiang, Chen Zhendong
Department of Oncology, The Second Affiliated Hospital of Anhui Medical University Hefei 230601, Anhui, China.
Am J Transl Res. 2024 Jun 15;16(6):2711-2718. doi: 10.62347/PHYS4309. eCollection 2024.
This study aims to explore the implications of serum miR-34a in breast cancer (BC) and its predictive value for the efficacy of neoadjuvant chemotherapy (NACT).
A retrospective analysis was performed on 102 female BC patients (research group) admitted to The Second Affiliated Hospital of Anhui Medical University between January 2016 to March 2018 and 102 concurrent female health controls who underwent physical examinations (control group). Serum samples from both groups were subjected to quantitative reverse transcription polymerase chain reaction to measure miR-34a expression. The correlation of miR-34a with BC patients' clinical parameters was analyzed, and the implications of miR-34a for diagnosing BC and predicting NACT efficacy were assessed by receiver operating characteristic curves. Logistic regression analysis was employed to determine whether miR-34a independently influenced treatment effectiveness and patient outcomes.
The data showed significantly lower miR-34a levels in the research group than in the control group (P<0.05). The area under the curve (AUC) of miR-34a for differentiating BC was 0.888. In BC patients, miR-34a was strongly correlated with tumor staging and differentiation degree. Following NACT, BC patients showed an evident rise in miR-34a expression, with higher levels in patients with effective treatment compared to those with treatment failure (P<0.05). The AUC values of serum miR-34a in predicting the efficacy of neoadjuvant chemotherapy from FD to SD and from SD to TD were 0.880 and 0.861, respectively (P<0.001). Furthermore, patients with favorable prognosis exhibited markedly higher serum miR-34a expression than those with poor prognosis (P<0.05). The AUC of miR-34a expression for predicting adverse prognosis was 0.825. Decreased miR-34a was identified as an independent risk factor for treatment failure and poor prognosis.
Taken together, serum miR-34a is downregulated in BC and can predict the clinical progression of BC patients and the therapeutic efficacy of NACT.
本研究旨在探讨血清miR - 34a在乳腺癌（BC）中的意义及其对新辅助化疗（NACT）疗效的预测价值。
对2016年1月至2018年3月期间安徽医科大学第二附属医院收治的102例女性BC患者（研究组）和102例同期接受体检的女性健康对照者（对照组）进行回顾性分析。对两组的血清样本进行定量逆转录聚合酶链反应，以检测miR - 34a的表达。分析miR - 34a与BC患者临床参数的相关性，并通过受试者工作特征曲线评估miR - 34a对BC诊断及NACT疗效预测的意义。采用逻辑回归分析确定miR - 34a是否独立影响治疗效果和患者预后。
数据显示研究组中miR - 34a水平显著低于对照组（P<0.05）。miR - 34a区分BC的曲线下面积（AUC）为0.888。在BC患者中，miR - 34a与肿瘤分期和分化程度密切相关。NACT后，BC患者miR - 34a表达明显升高，治疗有效的患者水平高于治疗失败的患者（P<0.05）。血清miR - 34a预测新辅助化疗从疾病进展（FD）到疾病稳定（SD）以及从SD到疾病缓解（TD）疗效的AUC值分别为0.880和0.861（P<0.001）。此外，预后良好的患者血清miR - 34a表达明显高于预后不良的患者（P<0.05）。miR - 34a表达预测不良预后的AUC为0.825。miR - 34a降低被确定为治疗失败和预后不良的独立危险因素。
综上所述，血清miR - 34a在BC中表达下调，可预测BC患者的临床进展及NACT的治疗疗效。
